Lazard Asset Management’s Vaxcyte PCVX Stock Holding History

Lazard Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43M	Sell	41,843 -5,180	-11%	-$281K	﹤0.01%	902
2026 Q1	$2.73M	Sell	47,023 -17,955	-28%	-$975K	﹤0.01%	765
2025 Q4	$3M	Sell	64,978 -54,114	-45%	-$2.42M	0.01%	717
2025 Q3	$4.29M	Sell	119,092 -393,043	-77%	-$13M	0.01%	624
2025 Q2	$16.6M	Sell	512,135 -45,659	-8%	-$1.5M	0.02%	442
2025 Q1	$21.1M	Buy	557,794 +71,030	+15%	+$5.68M	0.03%	338
2024 Q4	$39.8M	Buy	+486,764	New	+$48.3M	0.06%	229
2023 Q3	–	Sell	-9,268	Closed	-$461K	–	2428
2023 Q2	$461K	Buy	+9,268	New	+$439K	﹤0.01%	1143
2023 Q1	–	Sell	-7,741	Closed	-$371K	–	2485
2022 Q4	$371K	Buy	+7,741	New	+$304K	﹤0.01%	1176

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Lazard Asset Management's PCVX Position: Q2 2026 in Review

Lazard Asset Management reduced its Vaxcyte (PCVX) stake by 11% in Q2 2026, selling an estimated $281K and leaving 41,843 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #902.

Lazard Asset Management first reported a position in PCVX in Q4 2022 and has held it in 9 quarters since. The position peaked at $39.8M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Lazard Asset Management held 41,843 shares of Vaxcyte worth $2.43M as of Q2 2026.
Lazard Asset Management sold 5,180 Vaxcyte shares in Q2 2026, an estimated $281K.
Vaxcyte made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #902 holding.
Lazard Asset Management first reported a position in Vaxcyte in Q4 2022 and has held it in 9 quarters since.
Lazard Asset Management's Vaxcyte position peaked at $39.8M in Q4 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.